Children with CKD have a significant burden, including fatigue and sleep disturbances.

Published Date: 13 Mar 2023

A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...

Read Full News

Latest News

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

CAR T-Cell Therapy Enabled Kidney Transplant in Highly Sensitized Patients

Strategy offers hope for hard-to-match patients

Todays Updates

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

Todays Updates

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

Latest News

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

Strategy offers hope for hard-to-match patients

News All Time

Make the Diagnosis: Chest Pain, Dyspnea, Palpitations, and More: What’s Her Diagnosis?

A 45-year-old woman presented to the emergency department with complaints of chest pain, heart palpitations that developed earlier that day, and dyspnea that began 3 days prior and had progressed. Can you diagnose the patient?

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

First Oral Carbapenem Approved for Complicated UTIs

Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients

How Did a Patient Survive a Decade With Metastatic RCC?

Surgery had beneficial role

360 Dead in Outbreak; McConnell Still Hospitalized? FDA Rejects Kidney Disease Drug

Health news and commentary gathered by MedPage Today staff

US FDA Declines to Approve Unicycive's Kidney Disease Drug

Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to ⁠treat elevated phosphate levels in chronic kidney disease patients on...

The Chatbot Will See You Now: A Crisis in Trust?

When healthcare feels out of reach, Europe’s patients are turning to AI for answers — and sometimes for the confidence to medicate themselves.

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Mineralys' Pill Cuts Blood Pressure in Kidney Disease Patients

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented ⁠at a major European...

Project Aims for Awareness of APOL1-Mediated Kidney Disease

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Kidney Cancer: Current Treatment Approaches Using Targeted Agents and Immunotherapy

Kidney Cancer: Current Treatment Approaches Using Targeted Agents and Immunotherapy

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Recommended News For You

Combination therapy improves outcomes for advanced triple-negative breast cancer

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances

Stem Cell Selection Unneeded for SSc Transplant Therapy?

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.

Ranking of the Best US Hospitals for Psychiatric Care.

Why are so many young adults getting cancer?

Recommended Articles For You

Unlocking the Potential of CPK Levels: How to Maximize Your Health Benefits 

Healthy Hematopoietic Aging and Disease Avoidance: Mechanisms, Clinical Insights, and Future Directions 

Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications 

IGSF8: A Rising Star in Cancer Immunotherapy - Harnessing the Innate Immune System 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Taking Charge of Your Cancer Journey.

2.

Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma

3.

Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.

4.

Trump Issues Gag Order for CDC, FDA; Stalled Hearing for RFK Jr.; Sex After Cancer

5.

"We Caught It Early": Advantage or Disadvantage?

1.

How HLH is Revolutionizing Healthcare

2.

Unlocking the Unknown: A Comprehensive Guide to Stage 4 Vulvar Cancer

3.

The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide

4.

Personalized Cancer Vaccines: The Next Frontier in Precision Oncology

5.

Exploring the Unknown: Unveiling the Mysteries of GIST Tumors

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

2.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

5.

Navigating the Complexities of Ph Negative ALL - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot